Researchers identify a key prognostic biomarker in MIBC that may predict disease outcomes, treatment efficacy in patients.
Muscle Invasive Urothelial Carcinoma
Latest News
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Drs. Galsky and Tawagi discuss the NIAGARA trial on perioperative durvalumab in combination with chemotherapy for MIBC.
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
At the Oncology Forum, Dr. Sanjay Juneja led a dynamic discussion covering pivotal developments across genitourinary cancers.
Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Trending
TAR-200 alone was compared with TAR-200 in combination with a PD-1 inhibitor to determine the efficacy of the treatment.
Dr. Gopa Iyer discusses his investigation of the relationship between DDR, mUC molecular subtypes and survival outcomes.
The outcomes of laUTUC for those with cT3-4 cM0 or cN1-2 cM0 disease are similar for both open and minimally invasive RNU.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.